# A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorecta

Source: https://onco.cc/trials/nct07796763/  
OnCo record `nct07796763` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Jiangsu HengRui Medicine Co., Ltd., not yet recruiting.

## Summary

A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2 is a phase 2, randomised interventional study registered as NCT07796763 by Jiangsu HengRui Medicine Co., Ltd., with a registry enrolment figure of 48 participants, started 2026-11-01 and due to reach its primary completion in 2028-05-01. Interventions recorded: Trastuzumab Rezetecan (SHR-A1811) injection; high dose; Trastuzumab Rezetecan (SHR-A1811) injection; low dose. Conditions listed: Advanced Colorectal Cancer Expressing HER2. Primary outcome: Incidence of treatment-emergent adverse events; Determination of the recommended phase 3 dose. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed unresectable, recurrent, or metastatic colorectal adenocarcinoma that is HER2-positive". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: HORIZON-CRC221
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07796763
- Phase: 2
- Setting: A Global, Multicenter, Randomized, Dose-Optimization Phase II Study of Trastuzumab Rezetecan (SHR-A1811) in Combination With mFOLFOX6 (-1) and Bevacizumab as First-Line Treatment in Patients With HER2-Positive Advanced Colorectal Cancer (HORIZON-CRC221)
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT07796763: https://clinicaltrials.gov/study/NCT07796763

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [HER2-amplified colorectal cancer](https://onco.cc/cancers/her2-amplified-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07796763.json